



STATE OF TENNESSEE
BUREAU OF TENNCARE
DEPARTMENT OF FINANCE AND ADMINISTRATION
310 GREAT CIRCLE ROAD
NASHVILLE, TENNESSEE

Memo

To: All TennCare Providers
From: Bureau of TennCare
Date: November 21, 2006
Re: Januvia® PDL Update

Effective December 5, 2006, Januvia® (sitagliptin) will become a **non-preferred** product on the Preferred Drug List for the TennCare Pharmacy Program and will be subject to clinical criteria. Patients currently on Januvia® will be grandfathered indefinitely. However, all patients started on Januvia® on or after December 5, 2006 will require a prior authorization. The current clinical criteria for Januvia® states:

The DPP-4 inhibitors will be approved only when **all** of the following have been met:

- Recipient has a diagnosis of Type II diabetes
- A1C level is greater than 7%, and
- Recipient has failed to obtain glycemic control on an adequate trial of therapy with the following agents:

- a) A biguanide product (i.e. metformin) - unless the patient has a contraindication, intolerance, adverse reaction, or other rationale for not being a candidate for metformin therapy

AND

- b) At least two other oral hypoglycemic agents (in two different classes listed below) - unless the patient has a contraindication, intolerance, adverse reaction, or other rationale for not being able to take the following oral agents:
 - Sulfonylurea
 - TZD
 - Meglitinide
 - Alpha glucosidase inhibitor

For patients who are grandfathered, an automatic system “look-back” will look for a Januvia® claim within the past 60 days. If the system does not see a claim for Januvia® within 60 days, the recipient’s grandfathering status is void and a prior authorization will then be needed. The updated PDL and clinical criteria can be downloaded at the TennCare/First Health website at <https://tennessee.fhsc.com>.

Thank you for your participation in the TennCare program and your commitment to assist your patients as we implement the reforms necessary to bring program costs in line with available funding.

<p>Please forward or copy the information in this notice to all providers who may be affected by these processing changes.</p>
